For citations:
Petrova A.N., Lomaia E.G., Morozova E.V., Shukhov O.A., Chelysheva E.Yu., Vlasova Yu.Yu., Kuzmina E.A., Kulemina O.V., Nemchenko I.S., Bykova A.V., Sudarikov A.B., Kokhno A.V., Turkina A.G. Results of asciminib therapy as part of managed access program in patients with chronic myeloid leukemia with T315I mutation. Oncohematology. 2025;20(2):53-66. (In Russ.) https://doi.org/10.17650/1818-8346-2025-20-2-53-66
Email this article 